Morningstar

Cantargia Announces Changes in Number of Shares and Votes

Provided by ACCESS Newswire

LUND, SE / ACCESS Newswire / July 31, 2026 / Cantargia AB (publ) ("Cantargia") (Nasdaq Stockholm:CANTA) today announced that the number of shares and votes in Cantargia has changed due to the recently completed rights issue (for further information, see the company's press release from June 23, 2026). Through the rights issue, the number of shares and votes increased by 33,333,333. Today, on the last trading day of the month, the number of shares and votes in Cantargia amounts to 281,944,988.

For further information, please contact
Hilde Steineger, CEO
Telephone: +46 (0)46-275 62 60
E-mail: info@cantargia.com

This information is information that Cantargia is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2026-07-31 10:00 CEST.

About Cantargia
Cantargia AB (publ), reg. no. 556791-6019, is a biotechnology company that develops antibody-based treatments for life-threatening diseases and has established a platform based on the protein IL1RAP, involved in a number of cancer forms and inflammatory diseases. Cantargia's oncology program, the antibody nadunolimab (CAN04), is being studied clinically, primarily in combination with chemotherapy with a focus on pancreatic cancer and non-small cell lung cancer. Positive data for the combinations indicate stronger efficacy than would be expected from chemotherapy alone. Cantargia's second development program, the antibody CAN10, blocks signaling via IL1RAP in a different manner than nadunolimab and addresses treatment of serious autoimmune/inflammatory diseases. In September 2025, the acquisition of CAN10 by Otsuka Pharmaceutical was completed.

Cantargia is listed on Nasdaq Stockholm (ticker: CANTA). More information about Cantargia is available at www.cantargia.com.

Attachments
Cantargia Announces Changes in Number of Shares and Votes

SOURCE: Cantargia



View the original press release on ACCESS Newswire

The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.

Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.

Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.

Popular

The 10 Best Companies to Invest in Now

The stocks of these high-quality companies look cheap today.
Tori Brovet

14 Elite Funds and ETFs, and 5 Popular Funds That Just Missed the Mark

Russ Kinnel shares investment ideas from his annual Thrilling Funds list and discusses how he screens for quality investments in a sea of options.
Russel Kinnel and Ivanna Hampton

4 Stocks to Buy Before They Rise Further

Plus, the member of the triple-digit club reporting earnings this week.
David Sekera, CFA and Susan Dziubinski

The Top Funds for a Simpler Retirement Portfolio

For retirement savers and retirees, Christine Benz highlights all-in-one funds and core funds that can serve as building blocks for a streamlined portfolio.
Christine Benz

The 10 Best Dividend Stocks

These are the top dividend-paying stocks to buy today.
Susan Dziubinski

Sponsor Center